Springer, Private Bag 65901, Mairangi Bay, 0754, Auckland, New Zealand.
Drugs. 2018 Dec;78(18):1931-1937. doi: 10.1007/s40265-018-1015-2.
Paratek Pharmaceuticals are developing omadacycline (NUZYRA™), a first-in-class orally active aminomethylcycline antibacterial, as a treatment for various bacterial infections. The drug, which is available in intravenous and oral formulations, has a broad spectrum of antibacterial activity and was recently approved in the USA as a treatment for the treatment of community acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI) in adults. This article summarizes the milestones in the development of omadacycline leading to this first global approval for the treatment of CABP and ABSSSI.
Paratek 制药公司正在开发 omadacycline（NUZYRA™），这是一种首创的口服活性氨甲基环素类抗菌药物，用于治疗各种细菌感染。该药物有静脉注射和口服两种剂型，具有广谱抗菌活性，最近在美国获得批准，用于治疗成人社区获得性细菌性肺炎（CABP）和急性细菌性皮肤和皮肤结构感染（ABSSSI）。本文总结了 omadacycline 开发过程中的重要里程碑，最终使其在全球范围内首次获批用于治疗 CABP 和 ABSSSI。
